WRBC
EUCR

W.R. Berkley Corp’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

W.R. Berkley Corp’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-119,047
Closed -$1.19M – 390
2022
Q3 		$1.19M Hold
119,047
– – 0.06% 319
2022
Q2 		$1.18M Hold
119,047
– – 0.06% 315
2022
Q1 		$1.17M Buy
119,047
+79,149
+198% +$777K 0.06% 320
2021
Q4 		$389K Buy
+39,898
New +$391K 0.02% 487

Other funds holding EUCR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

W.R. Berkley Corp's EUCR Position: Q4 2022 in Review

W.R. Berkley Corp sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 119,047 shares — an estimated $1.19M sold.

W.R. Berkley Corp first reported a position in EUCR in Q4 2021 and held it in 4 quarters. The position peaked at $1.19M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

  • W.R. Berkley Corp reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • W.R. Berkley Corp sold 119,047 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $1.19M.
  • W.R. Berkley Corp first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2021 and held it in 4 quarters.
  • W.R. Berkley Corp's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $1.19M in Q3 2022.
  • 5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on W.R. Berkley Corp's 13F filing for Q4 2022, filed 14 Feb 2023.